Aurora’s First Year Sales Of $3.46 Million In 2015 Surpassed Aphria’s 2015 Revenue Of $2.72 Million By A Good Margin.

The article adds that President Steve Dobler also has no relevant experience in the marijuana business and was noted by colorado pot business Grumpey Bear as a past business partner of Booth. Grumpey Bear remarked that ex-director Marc Levy worked to “aggressively promote Aurora in order to drive the share price higher” before selling his shares and leaving the company in August 2015. Final Thoughts As hopeful marijuana investors, we must ask ourselves; why should we take the risk of buying Aurora when we can invest in the renowned Canopy growth or the exceptionally managed Aphria? The answer, albeit obvious, comes down to Aurora’s low stock price and high percentage return that risk-loving investors can gain from it. Cannabis stocks as a whole are not trading on fundamentals in any sense of the word. From our following of cannabis tickers for the past year, we’ve learned that stock prices entirely follow news on legalization and the two highest valued marijuana companies (Canopy and Aphria) are also leaders in sales revenue for the industry. Source: Bloomberg Since we have no way of forecasting Canadian politics in the short term, we have to look for correlation between sales revenue and stock price. Aurora’s first year sales of $3.46 million in 2015 surpassed Aphria’s 2015 revenue of $2.72 million by a good margin. If Aurora is able to surpass Apria’s current TTM sales revenue in 2017, we believe there is high potential for Aurora to double from its current price in the next 9-12 months. Of course, this capital appreciation would come along more smoothly if upcoming news on legalization are positive. Personally, we do not have the risk tolerance to initiate a position in Aurora.

To read more visit

Comments are closed.